You are here

Zofran (Ondansetron)



Anitemetic, Serotonin Receptor Antagonist, 5-HT3


Supplied 4mg/2ml (2mg/ml)

Adult: 4 mg slow IV/IM, no less than 30 seconds; recommended over 2-5 minutes.

For patients greater than 40 kg, 4 mg IV over 2-5 minutes
For patients less than 40 kg. - 0.1mg/kg over 2-5 minutes

Antiemetic - The mechanism by which ondansetron works to control nausea and vomiting is not fully understood; it is believed that the antiemetic properties occur as a result of serotonin receptor antagonism.

Nausea and vomiting due to chemotheropy.
Prophylactic use prior to administration of pain management medication.
Nausea and vomiting with moderate to severe dehydration or electrolyte imbalance.

History of allergic reaction to ondansetron or to any medicine similar to ondansetron, including dolasetron (Anzemet), granisetron (Kytril), or palonosetron (Aloxi).

- Liver disease (metabolizes in the liver)
- Breast-feeding (passes through breast milk)
- Pregnancy (no adverse effects are known)
- Patients with a history, or family history, of Long QT syndrome; transient EKG changes have been seen with IV administration including QT interval prolongation.

- GI: Constipation, diarrhea, dry mouth
- Neurological: Headache, dizziness, drowsiness/sedation
- Immunological: Anaphylaxis (rare)
- Other: Fatigue, malaise, chills
- Cardiovascular: Cardiac dysrhythmia (rare), hypotension
- Respiratory: Bronchospasm
- Musculoskeletal: Muscle pain

Adverse reactions seen in patients receiving ondansetron have typically been noted at doses significantly higher than are used in protocol and in patients receiving the medication for longer periods of time.

Ondansetron may precipitate at the stopper/vial interface in vials that are stored upright. Potency and safety are not affected. If precipitate is observed, re-dissolve by shaking the vial vigorously.

Copyright © 2007-2016 Nabil El Sanadi. All rights reserved. does not provide medical advice, diagnosis or treatment. See additional information.